Creative Planning
AXDX icon

Creative Planning’s Accelerate Diagnostics AXDX Stock Holding History

Creative Planning’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$19K – 2028
2017
Q2 		$19K Buy
+200
New +$54.2K ﹤0.01% 3212

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Polar Capital
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Creative Planning's AXDX Position: Q3 2017 in Review

Creative Planning sold out of Accelerate Diagnostics (AXDX) in Q3 2017, closing a stake of 316 shares — an estimated $86K sold.

Creative Planning first reported a position in AXDX in Q2 2013 and held it in 12 quarters. The position peaked at $273K in Q3 2014. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2017.

  • Creative Planning reported no remaining Accelerate Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 316 Accelerate Diagnostics shares in Q3 2017, an estimated $86K.
  • Creative Planning first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 12 quarters.
  • Creative Planning's Accelerate Diagnostics position peaked at $273K in Q3 2014.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.